Mode of Bacterial Killing Affects the Inflammatory Response and Associated Organ Dysfunctions in a Porcine *E. coli* Intensive Care Sepsis Model

**CURRENT STATUS:** UNDER REVIEW

Paul Skorup  
Section of infectious diseases  
Corresponding Author  
ORCID: https://orcid.org/0000-0002-5407-6612

Lisa Maudsdotter  
Department of Molecular Biosciences, The Wenner-gren Institute, Stockholm University, Stockholm

Miklós Lipcsey  
Hedenstierna laboratory, Anesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala university, Uppsala

Anders Larsson  
Section of Clinical Chemistry, Department of Medical Sciences, Uppsala University, Uppsala

Jan Sjölin  
Section of Infectious Diseases, Department of Medical Sciences, Uppsala University, Uppsala

**DOI:**  
10.21203/rs.3.rs-16020/v1

**SUBJECT AREAS**  
*Critical Care & Emergency Medicine*

**KEYWORDS**  
*Antibiotics, Bacteria, Sepsis, Cytokines, Inflammation, Porcine*
Abstract
Background Sepsis is often treated with penicillin-binding protein 3 (PBP-3) acting β-lactam antibiotics, such as piperacillin-tazobactam, cefotaxime and meropenem. They cause considerable bacterial structural changes and have in vitro been associated with an increased inflammatory response. In a clinically relevant large animal sepsis model our primary aim was to investigate whether bacteria killed by a PBP-3 active antibiotic has a greater effect on the early inflammatory response and organ dysfunction compared with corresponding amounts of live or heat-killed bacteria. A secondary aim was to determine whether the addition of an aminoglycoside could mitigate the cefuroxime-induced response.

Method Killed or live *Escherichia coli* were administrated as a 3-hour (h) infusion to 16 healthy pigs in a prospective, placebo-controlled interventional experimental study. Cefuroxime was chosen as the PBP-3 active antibiotic and tobramycin represented the aminoglycosides. The animals were randomized to receive I) bacteria killed by cefuroxime, II) live bacteria, III) bacteria killed by heat or IV) bacteria killed by the combination of cefuroxime and tobramycin. Plasma endotoxin, tumor necrosis factor alpha, interleukin-6, interleukin-10, leukocytes and organ function were recorded at the start of the experiment and then hourly for 6 h.

Results Differences in dynamics of concentration over time between the four treatment groups were found for the three cytokines (p<0.001). Animals receiving cefuroxime-killed bacteria demonstrated higher responses than those receiving live or heat-killed bacteria (p<0.01). The addition of tobramycin reduced the cefuroxime-induced responses (p<0.001). The cytokine responses were associated with leucocyte activation that was further associated with pulmonary dysfunction and increases in lactate (p<0.01).

Conclusions In comparison with live or heat-killed bacteria, bacteria killed by a PBP-3 active antibiotic induced an increased inflammatory response associated with deteriorated organ and cellular function. The addition of an aminoglycoside to the PBP-3 active antibiotic reduced that response.

Background
Sepsis is a clinical syndrome of potentially life-threatening organ dysfunction caused by a
dysregulated host response to an infection. This syndrome is the most common cause of mortality in critically ill patients [1, 2]. In models of experimental Gram-negative sepsis the inflammatory response is enhanced after administration of antibiotics [3-5]. Similarly, a recent clinical study reported impairment within hours (h) after antibiotic administration in a large proportion of intensive care patients with sepsis [6]. The most common explanation for this phenomenon has been antibiotic-induced endotoxin release during the killing process, an event that has been extensively demonstrated in vitro [7-9]. Still, evidence of antibiotic-induced endotoxin release in patients is limited and conflicting [10-12]. In fact, in a recent study using a large animal Gram-negative sepsis model antibiotic-induced inflammation and organ impairment were observed but without any notable differences in plasma endotoxin concentrations compared with control animals [5]. If variation in endotoxin levels after antibiotic treatment does not cause the differences in activation of the inflammatory response and clinical impairment in vivo, it may be hypothesized that other mechanisms such as antibiotic-induced structural alterations of the bacteria [13] may play an important role.

Antibiotics with affinity to penicillin-binding protein 3 (PBP-3), such as piperacillin-tazobactam, cefotaxime and meropenem, are commonly used for the treatment of sepsis [14, 15]. PBP-3-acting antibiotics result in marked bacterial structural changes [13, 16, 17] and in vitro have been associated with an increase in the inflammatory response [18, 19]. Using our large animal intensive care Gram-negative sepsis model [5, 20], the primary aim of the present study was to explore the in vivo effect of ex vivo antibiotic-induced structural changes and whether bacteria killed by a PBP-3-active antibiotic affect the early inflammatory response and organ dysfunction to a greater extent than a corresponding amount of live or heat-killed bacteria.

The recommendation by the Surviving Sepsis Campaign to start antibiotic treatment with two antibiotics with different modes of action [21] has been questioned by the Infectious Diseases Society of America (IDSA) Sepsis Task Force. One of the questions of interest here pertains to whether two antibiotics arrest inflammation more rapidly and effectively than one [22, 23]. A reduced effect on the inflammatory response by the addition of aminoglycosides to β-lactam antibiotics has only been
demonstrated in vitro. In these studies the underlying mechanism was believed to be a reduction of endotoxin release during the killing process [18, 19]. Therefore, a secondary aim was to study the in vivo effect on the inflammatory response of bacteria killed by a β-lactam-aminoglycoside combination in the absence of the killing-induced endotoxin liberation.

Methods
Animals and ethic statements
Sixteen clinically healthy landrace-breed piglets of both sexes were included. The study was approved by the Animal Ethics Committee in Uppsala, Sweden (permit no. C155/14), and all animals were handled in compliance with the Guide for the Care and Use of Laboratory Animals. Animals had access to water and food ad libitum until 1 h before the start of the experiment.

Anesthesia and preparations
The anesthetization preparation, maintaining of anesthesia and ventilation of animals were performed as in previously described procedures [5, 20]. An additional file describes this process in detail (Additional file 1). Before the experimental start, the animals were allowed a 40-minute (min) stabilization time. The intensive care provided a treatment protocol to maintain ventilation, anesthesia and circulation within preset limits, given in Additional file 2.

Organism
The Escherichia coli (E. coli) strain B09-11822 employed in this experiment (O-rough:K1:H7 Statens Seruminstitut, Copenhagen, Denmark) is a serum-resistant clinical isolate originally obtained from a patient with bloodstream infection [20]. According to the minimal inhibitory concentration test (Etest®; Biodisk, Solna, Sweden), this strain is sensitive to cefuroxime (4 µg x mL⁻¹) and tobramycin (0.5 µg x mL⁻¹).

Antibiotics
Because cefuroxime (Zinacef®, GlaxoSmithKline, Solna, Sweden) and tobramycin (Nebcina®, Meda, Solna, Sweden) have been used in previous in vivo studies on bacterial killing and endotoxin release using our model [5, 20], these antibiotics were allowed to represent PBP-3-active β-lactam antibiotics and aminoglycosides in the present study.

Experimental design
The study was prospective, parallel-grouped with animals randomized through the sealed envelope
technique into four treatment groups I) bacteria killed by cefuroxime, II) live bacteria, III) bacteria killed by heat and IV) bacteria killed by the combination of cefuroxime and tobramycin. Each group was comprised of four animals.

**Killing of bacteria** ex vivo before the animal experiment

A stem solution containing E. coli in the logarithmic phase at a concentration of $7.36 \pm 0.10 \log_{10}$ colony-forming units $\times mL^{-1}$ (mean ± accepted range) in saline was prepared. The bacterial concentration was assessed with the viable count technique.

The ex vivo pre-exposures are described in detail in an additional file (Additional file 3). Briefly, in group I (killed by cefuroxime) the bacterial stem solution was pre-exposed to cefuroxime for 4 h. After centrifugation, the fluid containing the liberated endotoxin during the killing process was removed and only the pellet of bacteria was resuspended in saline to the original stem concentration and then administrated to the animals.

In group II (live bacteria) the stem solution was infused into the animals without pre-exposure. The infused bacteria were kept in log phase by hourly replacement of the bacteria solution.

In group III (killed by heat) the bacterial stem solution was pre-exposed to 95°C for 10 min and, after having been cooled to room temperature, administrated to the animals.

In group IV (killed by cefuroxime + tobramycin) the bacterial stem solution was pre-exposed to cefuroxime in combination with tobramycin. To reduce the difference in the number of live bacteria in the infusate from that in group I the exposure time was reduced to 1 h. After that, the bacteria were treated in the same way as in group I.

**Bacterial count** before and after the pre-exposures was performed. A light microscope (x1000) was used to inspect the morphologic structures of the bacteria after pre-exposure in comparison with those of the live bacteria.

**Animal experiment**

The experimental protocol is depicted in Fig. 1. The final bacterial solutions were infused intravenously at a constant rate of 8.33 mL/h starting from baseline and continuing for 3 h. To kill the fraction of eventual remaining live bacteria antibiotics were provided as 20-min infusions 2 h after
baseline as follows: Group I and III received 50 mL saline plus 750 mg cefuroxime in 50 mL saline; group II received only 100 mL saline; and animals in group IV were administered 750 mg cefuroxime in 50 mL saline and an additional 7 mg x kg\(^{-1}\) tobramycin in 50 mL saline. Blood samples were collected at baseline and then at hourly intervals to determine the inflammatory response and cellular and organ function. Levels of endotoxin were measured at 0 h, 2 h, 4 h and 6 h. Inflammation was evaluated hourly by arterial concentrations of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10), leukocytes and hemoglobin while cellular dysfunction was assessed by arterial plasma lactate. Circulation was monitored continuously and recorded hourly by mean arterial pressure (MAP) and left ventricular stroke work index (LVSWI). Organ function was recorded hourly by plasma platelet count, arterial partial pressure of oxygen/inspired fraction of oxygen (PaO\(_2\)/FiO\(_2\)), static pulmonary compliance, plasma creatinine and urinary output. The animals remained anesthetized until sacrifice, which was done by an injection of potassium chloride at 6 h.

Analyses
The endotoxin analysis was performed by the Limulus amoebocyte lysate assay and cytokine analysis by the porcine-specific enzyme-linked immunosorbent assay. Details of the methodological analyses of the blood tests and monitoring of the organ parameters are presented in an additional file (Additional file 4).

Statistics
The primary endpoint was to study whether the dynamics in concentration of cytokines (TNF-α, IL-6, IL-10) differed between animals receiving bacteria killed by cefuroxime and those receiving live or heat-killed bacteria and secondary endpoint whether the inflammatory response was reduced after the addition of tobramycin. Comparing cytokine peak values with four animals in each group, a power of 0.8, a two-sided α-error of 0.05 and a standard deviation of 15%, the detectable difference was at least 30%. For non-cytokine values, the change from baseline was calculated. To evaluate differences between the treatment groups an analysis of variance (ANOVA) for repeated measures was performed using the group by time interaction term. If the interaction demonstrated significance when all four treatment groups were included, additional ANOVAs were conducted to test differences between the
treatment groups. Cytokine peak values were compared by one-way ANOVA. In the correlation analyses between the inflammatory response and changes in cellular and organ dysfunction at 3 h Pearson's correlation coefficient was calculated, except for creatinine, in which the Spearman rank correlation was applied.

IL-6, TNF-α and IL-10 concentrations are log-normally distributed [24] and thus these values were logarithmically transformed. Normally distributed data are expressed as mean ± SD. Non-normally distributed data are presented as median (range) with group comparisons performed by the Kruskal-Wallis test. Differences in provided amounts of norepinephrine were compared using the Mann-Whitney U test. A p-value of < 0.05 was considered significant. All calculations were performed using Statistica™ (v13.2, StatSoft, Tulsa, OK, USA).

Results

All animals developed signs of either sepsis or septic shock after initiation of the bacterial infusion as manifested by decreases in MAP, LVSWI, platelets, PaO₂/FiO₂ and pulmonary compliance and increases in lactate, hemoglobin and plasma creatinine (Table 1). (HERE Table 1 SHOULD APPEAR, but due to its size larger than one A4 it is now placed at the end of the document). Bodyweight, dose of infused bacteria, concentrations of remaining live E. coli in the infusate and blood bacterial count in vivo are summarized in Table 2.

Table 1

Parameters of inflammation, circulation and organ function in animals treated with either bacteria killed by cefuroxime alone (n = 4), live bacteria (n = 4), bacteria killed by heat (n = 4) or by a combination of cefuroxime + tobramycin (n = 4).

| Parameter/Treatment | Parameter | Baseline before challenge | 0 h | 1 h | 2 h | 3 h | 4 h | 5 h | 6 h |
|---------------------|-----------|---------------------------|-----|-----|-----|-----|-----|-----|-----|
| Leucocyte count (10⁹ x L⁻¹) | p all groups < 0.001; p cefur vs live NS; p cefur vs heat < 0.001; p cefur vs comb < 0.001 | Cefuroxime | 12.0 ± 2.9 | 3.7 ± 2.1 | 3.7 ± 1.7 | 3.5 ± 2.2 | 4.7 ± 2.5 | 5.3 ± 2.4 | 6.7 ± 2.1 |
| | | Live bacteria | 10.6 ± 6.3 | 5.3 ± 2.0 | 5.8 ± 1.3 | 7.3 ± 4.3 | 6.2 ± 1.3 | 5.9 ± 1.0 | 5.7 ± 1.1 |
| | | Heat | 9.2 ± 3.0 | 5.8 ± 1.1 | 4.3 ± 1.7 | 4.9 ± 1.0 | 5.6 ± 1.1 | 7.2 ± 1.7 | 10.5 ± 2.4 |
| | | Cefuroxime + tobramycin | 12.1 ± 3.6 | 6.9 ± 1.9 | 12.5 ± 4.2 | 12.4 ± 3.2 | 11.6 ± 2.2 | 11.1 ± 2.0 | 12.8 ± 2.5 |
| Hemoglobin (g x L⁻¹) | p all groups 0.016; p cefur vs live NS; p cefur vs heat NS; p cefur vs comb < 0.01 | Cefuroxime | 74 ± 5 | 94 ± 9 | 100 ± 7 | 105 ± 12 | 106 ± 10 | 110 ± 14 | 109 ± 13 |
| | | Live bacteria | 79 ± 5 | 89 ± 11 | 99 ± 14 | 104 ± 10 | 105 ± 13 | 109 ± 16 | 103 ± 7 |
|                  | $\mu$ ± 5 | $\mu$ ± 11 | $\mu$ ± 14 | $\mu$ ± 18 | $\mu$ ± 13 | $\mu$ ± 10 | $\mu$ ± 7 |
|------------------|-----------|------------|------------|------------|------------|------------|----------|
| Heat             | 78 ± 8    | 96 ± 4     | 105 ± 1    | 108 ± 1    | 108 ± 6    | 104 ± 9    | 99 ± 5   |
| Cefuroxime + tobramycin | 73 ± 4    | 83 ± 5     | 84 ± 7     | 93 ± 10    | 93 ± 11    | 89 ± 9     | 86 ± 8   |
| Live bacteria    |           |            |            |            |            |            |          |
| Heat             | 93 ± 13   | 92 ± 11    | 95 ± 21    | 82 ± 21    | 85 ± 23    | 75 ± 14    | 73 ± 10  |
| Cefuroxime + tobramycin | 100 ± 9   | 100 ± 6    | 104 ± 6    | 113 ± 5    | 113 ± 9    | 104 ± 15   | 92 ± 18  |
| Static pulmonary compliance (mL x cmH2O−1) | 28 ± 7    | 20 ± 5     | 19 ± 7     | 15 ± 3     | 15 ± 5     | 17 ± 4     | 16 ± 3   |
| Heat             | 25 ± 5    | 20 ± 4     | 18 ± 5     | 16 ± 5     | 16 ± 5     | 16 ± 5     | 16 ± 3   |
| Cefuroxime + tobramycin | 23 ± 3    | 21 ± 2     | 21 ± 2     | 19 ± 2     | 19 ± 1     | 18 ± 1     | 18 ± 1   |
| PaO2/FiO2 (kPa)  | 343 ± 117 | 366 ± 147  | 345 ± 135  | 258 ± 125  | 217 ± 165  | 237 ± 145  | 248 ± 152|
| Heat             | 258 ± 4   | 281 ± 35   | 212 ± 25   | 162 ± 38   | 194 ± 35   | 208 ± 26   | 218 ± 28 |
| Cefuroxime + tobramycin | 286 ± 53  | 315 ± 48   | 300 ± 67   | 280 ± 59   | 283 ± 53   | 286 ± 53   | 282 ± 64 |
| Platelet count (109 x L−1) | 59 ± 10   | 53 ± 18    | 45 ± 14    | 52 ± 23    | 31 ± 24    | 36 ± 19    | 34 ± 18  |
| Heat             | 60 ± 4    | 54 ± 12    | 37 ± 15    | 32 ± 17    | 32 ± 14    | 32 ± 9     | 32 ± 8   |
| Cefuroxime + tobramycin | 60 ± 9    | 58 ± 10    | 53 ± 10    | 45 ± 13    | 36 ± 14    | 36 ± 6     | 34 ± 6   |
| Static pulmonary compliance (mL x cmH2O−1) | 24 ± 7    | 20 ± 5     | 19 ± 7     | 15 ± 3     | 15 ± 5     | 17 ± 4     | 16 ± 3   |
| Heat             | 25 ± 5    | 20 ± 4     | 18 ± 5     | 16 ± 5     | 16 ± 5     | 16 ± 5     | 16 ± 3   |
| Cefuroxime + tobramycin | 23 ± 3    | 21 ± 2     | 21 ± 2     | 19 ± 2     | 19 ± 1     | 18 ± 1     | 18 ± 1   |
| Plasma Creatinine (µmol x L−1) | 85 (71–90) | 78 (68–88) | 76 (65–83) | 77 (62–90) | 91 (58–112) | 101 (59–138) | 120 (60–159) |
| Heat             | 66 (61–121) | 64 (61–119) | 63 (59–117) | 64 (58–110) | 66 (60–104) | 73 (63–91) | 79 (68–90) |
| Cefuroxime + tobramycin | 77 (65–84) | 76 (63–81) | 74 (62–79) | 72 (61–78) | 72 (64–83) | 77 (69–85) | 79 (60–88) |
| Urine output (mL x h−1) | 55 (44–600) | 160 (65–480) | 84 (65–95) | 59 (11–160) | 28 (6–60) | 16 (10–33) | 16 (0–35) |
| Heat             | 310 (6–36) | 210 (70) | 45 (15–90) | 70 (23–120) | 45 (6–36) | 55 (7–65) | 55 (1–50) |
Table 2

Bodyweight, dose of infused bacteria and in vivo blood bacterial counts.

| Treatment                      | Bodyweight (kg) | Infused bacteria. | Infused bacterial dose (log_{10} CFU) | Blood bacterial count in vivo (log_{10} CFU x ml⁻¹) |
|--------------------------------|-----------------|-------------------|---------------------------------------|---------------------------------------------------|
|                                |                 |                   |                                       | 0 h       | 1 h       | 2 h       | 3 h       | 4–6 h     |
| Cefuroxime                     | 26.0 ± 2.0      | 8.78 ± 0.065      | < 0.5                                 | < 0.5     | < 0.5     | < 0.5     | < 0.5     | < 0.5     |
| Live E. coli                   | 24.7 ± 1.4      | 8.78 ± 0.07       | < 0.5                                 | 2.83 ± 0.38| 3.18 ± 0.48| 3.30 ± 0.53| < 0.5     | < 0.5     |
| Heat                           | 26.6 ± 1.5      | 8.71 ± 0.05       | < 0.5                                 | < 0.5     | < 0.5     | < 0.5     | < 0.5     | < 0.5     |
| Cefuroxime + tobramycin        | 25.5 ± 2.7      | 8.74 ± 0.05       | < 0.5                                 | < 0.5     | < 0.5     | < 0.5     | < 0.5     | < 0.5     |

Mean ± SD. CFU = colony-forming unit.
a These bacteria were not intended to be killed.

There were no differences in bacterial dose or animal weight between the treatment groups. A small fraction of live bacteria (< 0.1%) remained in the infusates exposed to heat or antibiotics but this did not result in positive blood bacterial count in vivo.

TNF-α, IL-6 and IL-10 dynamics

Concentrations of TNF-α, IL-6 and IL-10 are displayed in Fig. 2. At baseline, plasma TNF-α, IL-6 and IL-10 levels were close to the detection limit in all animals, increasing markedly during the study.

Plasma TNF-α and IL-10 reached peak concentrations at 1 h and IL-6 at 3 h. Thereafter, the concentrations continuously declined. Differences in dynamics of concentration over time between the four treatment groups were found for the three cytokines (all, p < 0.001). Bacteria pre-exposed to cefuroxime resulted in higher cytokine values over time for all three cytokines than live bacteria (all, p < 0.05) or bacteria pre-exposed to heat (all, p < 0.01). The addition of tobramycin notably reduced the cefuroxime-induced cytokine response (all, p < 0.001).

Cytokine peak values in the cefuroxime group were higher than in the combination group (all, p < 0.05). However, in contrast to animals administered live or heat-killed bacteria, the differences did
not reach statistical significance.

**Inflammation, circulation and organ dysfunction**

Decreases in leukocyte count, which reflect leukocyte activation [25, 26], and increases in hemoglobin, which reflect an increase in capillary permeability [27], differed significantly between the treatment groups, with the most prominent changes in the cefuroxime group and the most discrete changes in the combination group (Table 1).

The total dose of norepinephrine, provided as per the intensive care protocol, was higher in the cefuroxime group with a median dose of 2440 µg (range 60-4980), which was more than that given to animals administered live bacteria (median dose 0 µg, range 0–60) or bacteria killed by the combination antibiotic treatment that were not given any norepinephrine at all (both p < 0.05). For LVSWI, plasma lactate and organ function, there were more pronounced changes in the group pre-exposed to cefuroxime, although these differences were not statistically significant (Table 1). Other intensive care adjustments, such as increased FiO₂ or extra fluid boluses, were carried out in accordance with the treatment protocol without significant differences between the groups.

As shown in Table 3, the peak TNF-α and IL-6 values correlated with changes at 3 h in lactate, platelets and PaO₂/FiO₂. Similarly, the leukocyte response correlated with changes at 3 h in lactate and PaO₂/FiO₂. For changes in creatinine, these correlations were stronger at 6 h: 0.86 for TNF-α, 0.81 for IL-6 and − 0.64 for leukocyte peak responses.
### Table 3
Correlations between cytokines, leukocyte response and changes in hemoglobin, lactate and organ function variables.

| Variable          | Log IL-6 3h | Log IL-10 1h | Leukocytes 3−0h | Hemo-globin 3−0h | LVSWI 3−0h | Lactate 3−0h | Platelets 3−0h | Stat. pulm. compl. 3−0h | PaO₂/FiO₂ 3−0h | Creatinine 3−0h |
|-------------------|-------------|--------------|-----------------|------------------|------------|-------------|----------------|--------------------------|----------------|-----------------|
| Log TNF-α 1h      | 0.87***     | 0.71**       | -0.79***        | 0.32             | -0.57*     | 0.88***      | -0.63**        | -0.19                    | -0.62*          | 0.44            |
| Log IL-6 3h       | -           | 0.47         | -0.71**         | 0.34             | -0.61*     | 0.77***      | -0.65**        | -0.29                    | -0.78***         | 0.39            |
| Log IL-10 1h      | -           | -0.63**      | 0.14            | -0.27            | 0.55*      | -0.11        | -0.24          | -0.43                    | -0.05            |                |
| Leukocytes 3−0h   | -           | -            | -0.40           | 0.34             | -0.70**    | 0.38         | 0.49           | 0.77***                   | -0.07            |                |

LVSWΙ = Left ventricular stroke work index, Stat. pulm. compl. = static pulmonary compliance. Pearson’s correlation test was used, except in the correlations for creatinine in which Spearman’s rank correlation test was calculated.

*p < 0.05; **p < 0.01; ***p < 0.001.

Morphologic visualization of bacteria in the infused solutions and endotoxin levels

Microscopic investigation of the final infused solutions containing live bacteria, bacteria killed by heat or the combination of cefuroxime + tobramycin visualized bacteria that could not be differentiated in quantity or morphology from each other. In contrast, solutions with bacteria killed by cefuroxime alone demonstrated elongated thread-like bacterial filaments without visible damage to the membranes.

Endotoxin concentrations in the four treatment groups are listed in Table 4. The peak endotoxin concentrations at 2 h correlated with peak TNF-α, IL-6, IL-10 values and leukocytes response at 3 h with r-values of 0.88, 0.85, 0.42 and − 0.61, respectively (all, p < 0.05).
Table 4
Endotoxin levels at different time points.

| Treatment                  | Baseline, before challenge 0 h | 2 h         | 4 h         | 6 h         |
|----------------------------|---------------------------------|-------------|-------------|-------------|
| Cefuroxime                 | 1.53 ± 0.20                     | 2.98 ± 0.72 | 2.27 ± 0.50 | 1.98 ± 0.42 |
| Live bacteria              | 1.57 ± 0.28                     | 2.67 ± 0.39 | 2.21 ± 0.30 | 1.82 ± 0.09 |
| Heat                       | 1.83 ± 0.33                     | 2.76 ± 0.12 | 2.09 ± 0.26 | 1.77 ± 0.21 |
| Cefuroxime + tobramycin    | 1.50 ± 0.20                     | 2.08 ± 0.19 | 1.52 ± 0.15 | 1.50 ± 0.12 |
| Mean ± SD. Log EU x L-1    |                                 |             |             |             |

Discussion

Comparing with previously used rodent models [3, 4], the sepsis model used in the present study takes advantage of the porcine similarities to the human inflammatory response [28]. In addition, the model was further developed to resemble the situation for patients with sepsis admitted to an intensive care unit, where therapeutic actions such as sedation, mechanical ventilation and vasopressors may modify the inflammatory response [20, 29, 30]. Despite the mitigating effects of these intensive care measures and in the absence of the free endotoxin that has been shown to be liberated during the antibiotic-induced killing process in vitro [7], bacteria killed by the PBP-3-active antibiotic cefuroxime resulted in increased TNF-α and IL-6 responses compared with those caused by live, untreated bacteria. There were also significant cytokine-associated differences in leukocyte activation and capillary leakage. Although significant correlations do not establish causal relationships, the differences observed in the inflammatory response might be further linked to changes in cellular metabolism and organ function.

Because one dose of PBP-3-active antibiotics does not kill all bacteria [5, 7], some remaining live bacteria were also included in the infusate. Because of the low number of live bacteria relative to the number of killed bacteria and because of the extra dose of antibiotics administered after 2 h, it is unlikely that these live bacteria affected the cefuroxime-induced response. Moreover, a mixture of killed and live bacteria is an obvious phenomenon in vivo. Animals that were given cefuroxime-killed bacteria also demonstrated a higher inflammatory response than animals given heat-killed bacteria, which resulted in a response similar to that caused by live bacteria. This finding indicates that the cefuroxime-induced inflammatory increase was not elicited simply because the bacteria were not
IL-10, an early marker associated with the initiation of anti-inflammatory reactions, increased in parallel with TNF-α and IL-6, supporting initial activation of both pro- and anti-inflammatory responses in this model, which is similar to early clinical responses shown in intensive care patients with sepsis [31, 32]. IL-10 was consistently higher in the cefuroxime group as compared with the other groups. We hypothesize that the bacterial morphological appearance with elongation and formation of filamentous forms associated with PBP-3 activity described previously [16, 17, 33] and seen in the present experiment plays an important role in the induction of inflammation and organ dysfunction. Larger bacterial areas due to elongation most certainly increase the amount of pathogen-associated molecular patterns that can bind with extracellular domains on host inflammatory cells. Because the supernatants after treatment with antibiotics or heat were removed before infusion into the animals, the free endotoxin in this study probably originated from killed bacteria in vivo during the further process of fragmentation. The correlations between free endotoxin peak levels and TNF-α, IL-6 and leukocyte responses suggest that liberated endotoxin might contribute to the inflammatory response. However, a study on the porcine dose-response of cytokines to endotoxin [24] indicates that the limited concentration differences between the treatment groups would only result in a minor modification of the cytokine response.

Live bacteria are quickly eliminated from the circulation because of an effective immune system and the process of bacterial killing takes mainly place in the spleen and liver [20]. Using this intensive care model in a previous study, animals with live E. coli sepsis treated with cefuroxime demonstrated a more pronounced cytokine increase, leukocyte activation and organ dysfunction than control animals. These events occurred without any increase in plasma free endotoxin [5]. The increased inflammatory response might have been the result of the killing process with or without local endotoxin liberation in the liver and the spleen or the result of the antibiotic-killed bacteria per se. The present results support the findings of that study and further demonstrate that killed bacteria alone can elicit the inflammatory response and that the mechanism of the preceding killing results in inflammatory responses of different magnitudes.
Our results support Mock et al.’s clinical findings in which patients with Gram-negative sepsis treated with PBP-3-active antibiotics showed higher mortality than patients treated with antibiotics with little or no PBP-3 activity [34]. Randomized clinical studies comparing the effect of a PBP-3 active antibiotic with a non-PBP-3 active antibiotic have shown no or only trends towards differences in endotoxin levels, cytokines and outcomes [35–38]. However, considering the mild severity of sepsis and the low number of patients included in these studies, the chance of detecting a difference was minimal. A randomized clinical study specifically on patients with septic shock would be of value but has not yet been performed, probably because of the inherent difficulties in conducting such a study.

Nevertheless, the phenomenon of an antibiotic-induced inflammatory response and deterioration is in agreement with Mignon et al.’s study on intensive care patients with sepsis in which deterioration occurred in almost half of the patients within 4 h after the start of antibiotic treatment [6].

As has previously been shown in vitro [18, 19], this large animal study demonstrated that the addition of tobramycin reduced the cefuroxime-induced inflammatory response also in vivo. This effect seems to be mainly mediated by non-endotoxic effects. The morphologic elongation of bacteria seen after single PBP-3 active treatment was absent when tobramycin was added, which might explain this result. However, in agreement with several in vitro studies [7, 39, 40] the levels of endotoxin were lower in the combination group, suggesting that differences in endotoxin levels might have contributed to the reduced inflammatory response in the combination group. In addition to its binding to the ribosome causing mistranslation and misfolded membrane proteins as well as changes in the bacterial surface, the aminoglycoside-induced inhibition of endotoxin synthesis may play a role [13, 41]. These results, in conjunction with the finding of a more rapid killing [20], indicate that the beneficial effects of adding an aminoglycoside to a β-lactam antibiotic found in vitro also are seen in vivo. A more rapid killing and a decreased inflammatory response thus offer possible explanations to Kumar et al.’s clinical findings in which patients treated with the combination of a β-lactam antibiotic and an aminoglycoside demonstrated improved survival in comparison with propensity-matched control patients [42]. Although a theoretical experimental model, the results from this large animal intensive care model lend some support to the hypothesis that a combination of antibiotics may
arrest inflammation more rapidly and effectively than single treatment which was one of the questions raised by IDSA [22, 23] in their criticism of the Surviving Sepsis Campaign’s recommendation to combine antibiotics for the treatment of patients in septic shock [21].

Conclusions

E. coli killed by a PBP-3 active antibiotic induces an increased inflammatory response when compared with live or heat-killed bacteria. This effect seems to be mediated mainly by other mechanisms than endotoxin release. The increase in inflammation is associated with deteriorated organ and cellular function. The addition of an aminoglycoside reduces the PBP-3 active antibiotic-induced inflammatory response.

List Of Abbreviations

ANOVA: Analysis of variance; CFU: Colony-forming units; CI: Cardiac index; ELISA: Enzyme-linked immune-sorbent assay; E. coli: Escherichia coli; FiO2: Inspired fraction of oxygen; h: Hour; IDSA: Infectious Diseases Society of America; IL: Interleukin; LVSWI: Left ventricular stroke work index; MAP: Mean arterial pressure; MPAP: Mean pulmonary arterial pressure; min: Minutes; PaCO2: Arterial partial pressure of carbon dioxide; PaO2: Arterial partial pressure of oxygen; PBP-3: Penicillin-binding protein 3; PEEP: Positive end-expiratory pressure; TNF-α: Tumor necrosis factor alpha.

Declarations

Ethics approval and consent to participate

Ethical approval was obtained from the local animal ethics committee (application C155/14) and all animals were handled according to guidelines from the Animal Ethics Board (Uppsala, Sweden) and European Union directives for animal research.

Consent for publication

Not applicable.

Availability of data and material

Data are not collected from a public database. All relevant data are available upon request from the corresponding author

Competing interests

The authors declare that they have no competing interests.
Funding

This study was funded by grants from the Olinder-Nielsen Foundation, Jönköping, Sweden and the Uppsala University hospital research fund. Funding sources did not influence experimental protocol, data analysis or preparation of the manuscript.

Authors' contributions

Paul Skorup: Design of experiment, animal experiments, data collection, statistical analysis, preparation of the manuscript.

Lisa Maudsdotter Design of experiment, preparation and testing of bacterial strain, preparation of manuscript.

Miklos Lipcsey: Design of experiment, animal experiments, data collection, preparation of the manuscript.

Anders Larsson: Analysis of blood samples, preparation of the manuscript.

Jan Sjölin: Design of experiment, statistical analysis, preparation of the manuscript.

Acknowledgments

The authors thank Ayda Shams at the Uppsala Antibiotic Center and Monica Hall, Anders Nordgren, Agneta Roneus, Kerstin Ahlgren and all the staff at the Hedenstierna Laboratory for technical assistance. The study was performed at the Section for Clinical Research and the Hedenstierna Laboratory, Uppsala University, Uppsala, Sweden.

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801-10.

2. Martin GS. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther. 2012;10(6):701-6.

3. Bucklin SE, Morrison DC. Differences in therapeutic efficacy among cell wall-active antibiotics in a mouse model of gram-negative sepsis. J Infect Dis. 1995;172(6):1519-
4. Shenep JL, Mogan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis. 1984;150(3):380-8.

5. Skorup P, Maudsdotter L, Tano E, Lipcsey M, Castegren M, Larsson A, et al. Dynamics of endotoxin, inflammatory variables, and organ dysfunction after treatment with antibiotics in an Escherichia coli porcine intensive care sepsis model. Crit Care Med. 2018;46(7):e634-e41.

6. Mignon F, Piagnerelli M, Van Nuffelen M, Vincent JL. Effect of empiric antibiotic treatment on plasma endotoxin activity in septic patients. Infection. 2014;42(3):521-8.

7. Dofferhoff AS, Nijland JH, de Vries-Hospers HG, Mulder PO, Weits J, Bom VJ. Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study. Scand J Infect Dis. 1991;23(6):745-54.

8. Goto H, Nakamura S. Liberation of endotoxin from Escherichia coli by addition of antibiotics. Jpn J Exp Med. 1980;50(1):35-43.

9. Sjolin J, Gosclientski G, Lundholm M, Bring J, Odenholt I. Endotoxin release from Escherichia coli after exposure to tobramycin: dose-dependency and reduction in cefuroxime-induced endotoxin release. Clin Microbiol Infect. 2000;6(2):74-81.

10. Prins JM, Kuijper EJ, Mevissen ML, Speelman P, van Deventer SJ. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun. 1995;63(6):2236-42.

11. Giamarellou-Bourboulis EJ, Perdios J, Leleakis M, Eoconomou E, Tsouroulas P, Giamarellou H. Impact of cefuroxime administration on endotoxin (LPS) and tumour
necrosis factor-alpha (TNFalpha) blood levels in patients suffering from acute pyelonephritis: a preliminary report. Int J Antimicrob Agents. 1999;11(2):115-9.

12. Maury E, Barakett V, Blanchard H, Guitton C, Fitting C, Vassal T, et al. Circulating endotoxin during initial antibiotic treatment of severe gram-negative bacteremic infections. J Infect Dis. 1998;178(1):270-3.

13. Kohanski MA, Dwyer DJ, Collins JJ. How antibiotics kill bacteria: from targets to networks. Nat Rev Microbiol. 2010;8(6):423.

14. Breilh D, Texier-Maugein J, Allaouchiche B, Saux M-C, Boselli E. Carbapenems. J Chemotherapy. 2013;25(1):1-17.

15. Kocaoglu O, Carlson EE. Profiling of β-lactam selectivity for penicillin-binding proteins in Escherichia coli strain DC2. Antimicrob Agents Chemother. 2015;59(5):2785-90.

16. Macheboeuf P, Contreras-Martel C, Job V, Dideberg O, Dessen A. Penicillin binding proteins: key players in bacterial cell cycle and drug resistance processes. FEMS Microbiol Rev. 2006;30(5):673-91.

17. Goscinski G, Tano E, Löwdin E, Sjölin J. Propensity to release endotoxin after two repeated doses of cefuroxime in an in vitro kinetic model: higher release after the second dose. J Antimicrob Chemother. 2007;60(2):328-33.

18. Dofferhoff A, Esselink M, de Vries-Hospers H, Zanten Av, Bom V, Weits J, et al. The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother. 1993;31(3):373-84.

19. Norimatsu M, Morrison DC. Correlation of antibiotic-induced endotoxin release and cytokine production in Escherichia coli-inoculated mouse whole blood ex vivo. J Infect Dis. 1998;177(5):1302-7.

20. Skorup P, Maudsdotter L, Lipcsey M, Castegren M, Larsson A, Jonsson AB, et al.
Beneficial antimicrobial effect of the addition of an aminoglycoside to a beta-lactam antibiotic in an E. coli porcine intensive care severe sepsis model. PLoS One. 2014;9(2):e90441.

21. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-77.

22. Gilbert DN, Kalil AC, Klompas M, Masur H, Winslow DL. IDSA Position Statement: Why IDSA did not endorse the surviving sepsis campaign guidelines. Clin Inf Dis. 2017.

23. Klompas M. Monotherapy is adequate for septic shock due to gram-negative organisms. Crit Care Med. 2017;45(11):1930-2.

24. Lipcsey M, Larsson A, Eriksson MB, Sjolin J. Inflammatory, coagulatory and circulatory responses to logarithmic increases in the endotoxin dose in the anaesthetised pig. J Endotoxin Res. 2006;12(2):99-112.

25. Brown K, Brain S, Pearson J, Edgeworth J, Lewis S, Treacher D. Neutrophils in development of multiple organ failure in sepsis. Lancet. 2006;368(9530):157-69.

26. Aziz M, Jacob A, Yang W-L, Matsuda A, Wang P. Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol. 2013;93(3):329-42.

27. Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017;92(1):37-46.

28. Mair K, Sedlak C, Käser T, Pasternak A, Levast B, Gerner W, et al. The porcine innate immune system: an update. Dev Comp Immunol. 2014;45(2):321-43.

29. Wrigge H, Zinserling J, Stüber F, von Spiegel T, Hering R, Wetegrove S, et al. Effects of mechanical ventilation on release of cytokines into systemic circulation in patients with normal pulmonary function. Anesthesiology. 2000;93(6):1413-7.

30. Galley H, DiMatteo M, Webster N. Immunomodulation by anaesthetic, sedative and
analgesic agents: does it matter? Intensive Care Med. 2000;26(3):267-74.

31. Tamayo E, Fernandez A, Almansa R, Carrasco E, Heredia M, Lajo C, et al. Pro- and anti-inflammatory responses are regulated simultaneously from the first moments of septic shock. Eur Cytokine Netw. 2011;22(2):82-7.

32. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260-8.

33. Periti P, Mazzei T. Antibiotic-induced release of bacterial cell wall components in the pathogenesis of sepsis and septic shock: a review. J Chemotherapy. 1998;10(6):427-48.

34. Mock CN, Jurkovich GJ, Dries DJ, Maier RV. Clinical significance of antibiotic endotoxin-releasing properties in trauma patients. Arch Surg. 1995;130(11):1234-41.

35. Prins JM, van Agtmael MA, Kuijper EJ, van Deventer SJ, Speelman P. Antibiotic-induced endotoxin release in patients with gram-negative urosepsis: a double-blind study comparing imipenem and ceftazidime. J Infect Dis. 1995;172(3):886-91.

36. Luchi M, Morrison DC, Opal S, Yoneda K, Slotman G, Chambers H, et al. A comparative trial of imipenem versus ceftazidime in the release of endotoxin and cytokine generation in patients with Gram-negative urosepsis. J Endotoxin Res. 2000;6(1):25-31.

37. Byl B, Clevenbergh P, Kentos A, Jacobs F, Marchant A, Vincent J, et al. Ceftazidime- and imipenem-induced endotoxin release during treatment of gram-negative infections. Eur J Clin Microbiol. 2001;20(11):804-7.

38. Maskin B, Fontán PA, Spinedi EG, Gammella D, Badolati A. Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia. Crit Care Med. 2002;30(2):349-54.
39. Sjölin J, Gosinski G, Lundholm M, Bring J, Odenholt I. Endotoxin release from Escherichia coli after exposure to tobramycin: dose-dependency and reduction in cefuroxime-induced endotoxin release. Clin Microbiol Infec. 2000;6(2):74-81.

40. Gosinski G, Lundholm M, Odenholt I, Sjolin J. Variation in the propensity to release endotoxin after cefuroxime exposure in different gram-negative bacteria: uniform and dose-dependent reduction by the addition of tobramycin. Scand J Infect Dis. 2003;35(1):40-6.

41. Kusser WC, Ishiguro EE. Effects of aminoglycosides and spectinomycin on the synthesis and release of lipopolysaccharide by Escherichia coli. Antimicrob Agents Chemother. 1988;32(8):1247-50.

42. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010;38(9):1773-85.

Supplementary Information
Additional file 1. Anesthesia, ventilation, preparations and intensive care settings. (PDF xxx kb)
Additional file 2. Intensive care treatment protocol. (PDF xxx kb)
Additional file 3. Killing of bacteria ex vivo before the animal experiment, methodology. (PDF xxx kb)
Additional file 4. Detailed description of blood test analyses and monitoring of organ parameters. (PDF xxx kb)
Figures
Figure 1

The experimental protocol. The black bar represents an infusion of live or killed bacteria and the grey bar constitutes antibiotics given to eradicate eventual remaining live bacteria in groups I, III and IV. White arrows indicate time of sampling for bacterial quantification, cytokine concentrations and organ function parameters. Black arrows designate time of sampling for endotoxin concentrations.
Figure 2

Dynamics in cytokine concentration. Dynamics in concentration of TNF-α, IL-6 and IL-10 in animals during and after administration of killed or live E. coli in the following treatment groups (n=4 in each group): I) bacteria killed by cefuroxime alone II) live bacteria, III) bacteria killed by heat and IV) bacteria killed by the combination of cefuroxime and tobramycin. Data are shown as mean+SE. P-values are the results of the group-by-time interaction in the repeated-measures ANOVA after considering all time points.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

Additional file 3_Skorup manus 3_ver4 med nr_plaintxt.docx
Additional file 1_Skorup manus 3_ver3 med nr.docx
Additional file 4_Skorup manus 3_ver2_med nr_plaintxt.docx
Additional file 2_Skorup manus 3_ver3 med nr.docx